NCT01562483已完成2 期
The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain; a Randomized, Double Blinded, Placebo-controlled, Experiment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Average VAS pain
研究概览
简要总结
Persistent postsurgical abdominal pain (PPAP) is a very difficult to treat pain. This pain can persist for months or even years and significantly diminishes quality of life. The exact underlying cause for this pain persistence is still unclear, which makes its treatment still a challenge. The promising analgesic effects of Δ9-THC in previous research, plus the improved bioavailability of Namisol® in comparison with previous Δ9-THC substances form the basis of the present research proposal.
The current study aims to investigate the analgesic efficacy of Namisol® as add-on analgesic during a long-term treatment (52 days) of persistent postsurgical abdominal pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older
- •Pain should have developed after a surgical procedure
- •Pain duration exceeding 3 months, and average NRS≥3
- •Stable doses intake of analgesics for the past 2 months
- •The patient has been informed about the study, understood the information and signed the informed consent form
排除标准
- •Diagnosed irritated bowel syndrome (IBS) or chronic pancreatitis
- •Patient took cannabinoids on a regular basis for at least one year
- •Patient does not feel a pinprick test in the lower extremities
- •Patient has a body mass index (BMI) above 36,0 kg/m2
- •Patient suffers from serious painful conditions other than chronic pancreatitis
- •Patient has a significant medical disorder that may interfere with the study or may pose a risk for the patient
- •Patient uses any kind of concomitant medication that may interfere with the study or may pose a risk for the patient
- •Patient does not tolerate oral intake of medication or liquids, or is refrained from oral intake because of medical reasons
- •Patient demonstrates clinical relevant deviations in the electrocardiogram (ECG)
- •Patient has an actual moderate to severe renal impairment
- •Patient has an actual moderate to severe hepatic impairment
- •Patient has a presence or history of major psychiatric illness
- •Patient has experienced an epileptic seizure in the past
- •Patient demonstrates clinically significant laboratory abnormalities
- •Patient demonstrates a positive urine drug screen for THC, cocaine, MDMA, and amphetamines
- •Patient demonstrates a positive test result on hepatitis B surface antigen, hepatitis C antibody or HIV antibody test
- •Patient has a history of sensitivity / idiosyncrasy to THC
- •Patient has a known or suspected lactose intolerance
- •Female patient is pregnant or breastfeeding
- •Patient intends to conceive a child during the course of the study
- •Patient participates in another investigational drug study
- •Patient has a clinical significant exacerbation in illness
- •Patient is unwilling or unable to comply with the lifestyle guidelines
研究组 & 干预措施
delta-9-tetrahydrocannabinol (namisol)
Experimental
干预措施: Tetrahydrocannabinol (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Average VAS pain
时间窗: Baseline versus day 52
The primary outcome measure is defined as the reduction in average VAS pain scores at the end of the study (day 50-52) compared to the pre-treatment level between the Namisol® and placebo group, measured by a Visual Analoge Scale (VAS) in a pain diary.
次要结局
- Safety parameters(Baseline until follow-up (day 59-61))
- Quality of life(Baseline versus day 52)
- Quantitative Sensory Testing (QST)(Baseline versus day 15 and day 52)
- Electroencephalogram (EEG)(Baseline versus day 52)
- Depression and (pain related) anxiety(Baseline versus day 52)
- Pharmacodynamic parameters(Baseline versus day 15 and day 52)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
?9-THC (Namisol®) in persistent postsurgical paiPatients with persistent postsurgical abdominal painMedDRA version: 14.1Level: PTClassification code 10060932Term: Postoperative adhesionSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 14.1Level: PTClassification code 10000081Term: Abdominal painSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-000812-27-NLRadboud University Nijmegen Medical Centre68
已完成
2 期
The analgesic efficacy of Δ9-THC (Namisol®) in patients with persistent postsurgical abdominal pain: a randomized, double-blinded, placebo-controlled, parallel desigAbdominal postsurgical painadhesion pain10069888NL-OMON37384niversitair Medisch Centrum Sint Radboud68
进行中（未招募）
1 期
?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal PaiChronic pancreatitis with persistant abdominal painMedDRA version: 14.1Level: PTClassification code 10033649Term: Pancreatitis chronicSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-000730-19-NLRadboud University Nijmegen Medical Centre68
Unknown
2 期
Perioperative Δ9-THC for Postsurgical PainPainNCT01790555Radboud University Medical Center40
进行中（未招募）
1 期
Perioperative ?9-THC for postsurgical paiPatients undergoing elective major abdominal surgeryMedDRA version: 14.1Level: PTClassification code 10054799Term: Perioperative analgesiaSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10054711Term: Postoperative painSystem Organ Class: 100000004863EUCTR2012-005808-17-NLRadboud University Medical Centre40